Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. 
Body:
Aim (1): Protein kinase D1 (PKD1) is necessary for maintenance mammary luminal cell identity and loss of PKD1 results in reprogram luminal cell fate.
I. PKD1 IS A METASTASIS SUPPRESSOR GENE IN LUMINAL MCF7 CELL.
In our original application, we hypothesized that knockdown PKD1 in luminal MCF7 cells would induce epithelial to mesenchymal transition (EMT) and result in basal cell phenotypes. We have carried out multiple experiments at molecular and cellular levels to validate our hypothesis. [2, 3] . PKD1 can phosphorylate Snail at serine-11 and inhibit Snail transcription activity [4] . ( Summary: Our data strongly suggest that PKD1 is required to maintain epithelial identity of MCF7 cell. Knockdown PKD1 results in loss of expression of ER and Progesterone Receptor and switches MCF7 cells into basal-like cells via epithelial to mesenchymal transition (EMT). The resulting MCF7/shPKD1 cells have basal cell properties, such as molecular signature and cellular behavior. More importantly, the resulting MCF7/shPKD1 cells have more potential to form lung tumors. Our results suggest that PKD1 is a metastasis suppressor gene in luminal MCF7 cell. Although the mechanisms of PKD1 action on suppression EMT is still to be investigated, our previous studies suggest that transcription factor Snail is a potential downstream target for PKD1. As seen in Fig 1, the Snail S11V mutant, which mimics non-phosphorylated form, is the only isoform that can induce EMT in MCF7 cells and results in similar phenotype as knockdown PKD1.
(A) MCF7 stable cell lines that express wild-type (WT), S11E (mimic serine-11 phosphorylation), S11V (non-phosphorylation) mutant of Snai, a known EMT inducer

Fig 2. Loss of PKD1 induces EMT and downregulation of ER.(A) Western blotting analysis indicates that knockdown PKD1 leads to downregulation of expression of epithelial biomarkers, such as E-cadherin, -catenin, as well as ER. Expression of -catenin is increased. (B and C) Immunofluorescence imaging to confirm downregulation of ER (B) and E-cadherin (C) in
II.PKD1 IS A POTENTIAL ONCOGENE IN BASAL-LIKE BREAST CARCINOMAS.
We initially hypothesized that ectopic expression of PKD1 in aggressive breast cancer basal cell line MDA-MB-231, a PKD1 negative cell line could lower its tumorigenesis and metastasis abilities. We carried out a serial molecular, cellular and animal experiments and conclude that ove-expression of PKD1 in MB231 cell promotes tumorigenesis and metastasis. Thus, we have modified our hypothesis that PKD1 is a contextdependent tumorigenesis and metastasis repressor or enhance. Summary: Although the microarray and cellular behavior assays (clonogenic, migration and growth) data are somewhat confusing and contradictory, it is clear that the MB231/PKD1 cell has more potential in tumor formation and metastasis in mouse xenografts. These data suggest that PKD1 has a role in promoting tumor formation and metastasis in MB231 cell by a mechanism that reverse the MB231 cell back to stem cell like state with expression of AR. More molecular and cellular experiments are needed to confirm.
III. A POSSIBLE MOLECULAR MECHANISM FOR THE CELL-CONTEXT DEPENDENT PKD1 ACTIVITY.
To explain the dual role of PKD1 in MCF7 and MB231 cells, we think that one of our PKD1 studies provide some useful clues. In brief, PKD1 binds to E-cadherin in epithelial cell membrane and facilitate PKD1 activation. The kinetics of PKD1 activation is different in the presence or absence of E-cadherin. More importantly, PKD1 has different substrate phosphorylation profiles in the presence or absence of E-cadherin and it may suggest that PKD1 has distinct function in different cell types. A manuscript of the finding has been submitted to peer-reviewed journals for publication and is in Appendix 1.
Aim (2):
PKD1 function in mouse mammary tissue development. We will generate mammary tissue specific PKD1 deletion mice and examine abnormality in mammary gland.
We have established genotyping PCR for Cre, PKD1 Lox/Lox and P53 mut/mut (Fig 12) and we are able to breed mice with expected genotypes.
(a) Generation of PKD1 knockout mice. We have bred male MMTV-Cre mouse (NCI mouse repository, #01XA9, line F) with female PKD1 Lox/Lox (kindly provided by Dr Eric N. Olsen, University of Texas Southwestern Medical Center).  Propose an alternative hypothesis, other than stem cell or clonal evolution to explain the intra-tumor heterogeneity. Supported by this grant, we have collected experimental data to support our hypothesis.  Illustrate Protein kinase D1 role in breast cancers and may help designing personal therapeutic regimen for PKD1 positive and negative breast cancer.  To our best knowledge, we are the first to carry out PKD1 knockout experiment in mouse mammary tissue.
REPORTABLE OUTCOMES:
 One manuscript has been submitted for peer-reviewed journal (Appendix 1), one is in writing.  One postdoctoral researcher (Dr Zhuo Li) has been trained and now appointed as an oncological surgeon in a China hospital.  Multiple cell lines (two for MCF7/shPKD1, one for MDA-MB231/PKD1, one for SKBR3/PKD1). Multiple mouse knockout PKD1 mammary tissues and parallel control have been collected.  I myself is preparing next grant application based on the results from this award project.
CONCLUSION:
We have conducted comprehensive studies at molecular, cellular and animal model levels to illustrate our hypothesis that luminal type of breast cancer cell can be converted into basal-like cell by manipulating PKD1 signaling. In normal mouse mammary development, PKD1 expression is limited in luminal cell only. PKD1 functions in maintenance of epithelial cell identity. In luminal cancer cell line MCF7, loss of PKD1 results in downregulation of E-cadherin, ER and ER-regulated genes. Knockdown PKD1 in MMTV-Cre mice, the luminal cells (CK8 positive) express less ER and E-cadherin. More importantly, we have observed that 2/17 PKD1 KO mice develop breast and lung tumors, suggesting PKD1 plays a critical anti-cancer role in mammary gland. According to currently available data, we propose a mode of PKD1 action (left). The function of PKD1 in breast cancers is dual, in luminal type cancer, it has a cancer suppressor role; in basal-like cancer, it promotes tumor. Effects for further analysis of normal/cancer stem cells are hampered by lack of single distinct stem cell markers with anatomical position information, such as LGR5 in small intestine stem cell [6] . We have noted that many triple negative cancers and many basal-like cancer cell lines express PKD1, it is interesting to know how PKD1 contribute to tumor progression and metastasis. For future work on PKD1, I suggest: (1) test other promoter driven Cre (such as WAP-cre) to knockout PKD1 and study PKD1 function during pregnancy and lactation; (2) knockin PKD1 into mammary basal cells using CK14-Cre mouse with P53 mutant background. This mouse model may mimic some human triple breast cancer with P53 mutant and expressing PKD1 and this approach will help to understand how PKD1 acts in basal-type cancer cells; (3) using existing small molecule inhibitors for PKD1 to treat breast cancer in mouse models. As we suggest that expression of PKD1 in basal-like cancer cells promotes tumor progression, it is possible to inhibit PKD1 will suppress tumor; and (4) data mining to surrogate correlation of PKD1 expression with clinical outcomes of breast cancer patients with different genetic background and subtype of tumors. (3) . These adaptor proteins have in common the ability to bind specific PKC isozymes and connect them to a particular organelle or site in the cell (4).
Protein kinase D1 (PKD1), the founding member of PKD kinase family, is crucial for development since PKD1 knockout is embryonic lethal in mice (5) and the PKD1 function is not complemented by two close family members, PKD2 and PKD3. PKD family is classified within the calcium/calmodulin kinase (CAMK) superfamily, however, PKDs share many structural and regulatory similarities to the PKC family and previously identified as PKC family members (6,7). The PKD family members share certain basic structural features, including cysteine-rich region (C1 region, subdivided into C1a and C1b regions), a pleckstrin homology (PH) domain and catalytic domain (6, 7) . Like PKC, PKDs show no or low catalytic activity in unstimulated cells through an autoinhibition mediated by the PH domain (8) . Previous studies have demonstrated a general model of activation of PKD1 (7) . In brief, PKCs and PKD1 are recruited to the membrane surface in response to second messenger DAG. Activation of PKD is dependent on PKC activity to phosphorylate two key serine residues at PKD1 activation loop (Ser-
Furthermore, dextran sulfate, a potent PKD1 agonist, increases high level S916 phosphorylation, but low/none Ser-744/748 phosphorylation (11) .
Although phosphorylation plays a major role in PKD1 signaling efficiency or specificity, docking interactions with protein scaffolds or protein substrates also may contribute to the allosteric control of PKD1 activity (12) . The A-kinase anchoring protein AKAP-Lbc assembles an activation complex including PKD1, PKCeta and PKA in cardiomyocytes. In this protein complex, PKD1 is activated by nearby localized PKC and release from the complex mediated by PKA activity (13) . PKD1 was previously reported to co-localize and co-purify with E-cadherin, a major protein component in cell-cell adherens junctions (14) . In this study, we show E-cadherin facilitates PKD1 plasma membrane translocation and activation.
MATERIALS AND METHODS
Plasmid constructs: The GFP-PKD1 was described previously (14) . The P281G-PKD1 [equivalent to mouse PKD1 P287 (9,15)] which contains a point mutation in proline-281 into glycine residue in the C1b domain was generated by PCR-based mutation with Quikchange kit (Stratagene). The primer used (forward) 5'-GTCATCCACTCCTACACCCGGGCCACA GTGTGCCAGTACTGCAAG. The NLS-PKD1 was generated by inserting SV40 nuclear localization signal (NLS, with amino acid sequence PKKKRKV) downstream of GFP. Mem-PKD1 was created by inserting the sequence encoding the first 20 amino acid residues of neuromodulin upstream of GFP-PKD1 (Fig 1A) . Detail methods and primer sequences are available on request.
Ecadherin CTF2-pcDNA3 construct (Ref (17) , Fig 3A) was kindly provided by Dr Y. Fujita, University College London. This construct contains the whole intracellular domain. IL2R-EcadC (Fig 3A) is a chimera that fuses the extracellular and transmembrane domains of the interleukin-2 receptor  subunit to the cytoplasmic domain of E-cadherin (Ref (18), kindly provided by Dr. C. Gottardi, Northwestern University). For yeast twohybrid assay, the pGBK-T7 plasmid (Clontech) containing C1a, C1b, PH and catalytic domains of PKD1 were described previously (19) . E-cadC-pGAD-T7 vector contains part of trans-membrane and whole intracellular domain of E-cadherin (amino acid residues 716-883). A full-length E-cadherin expression vector (Fig 3A) was obtained from Addgene.org (Plasmid #18804). ShRNAs targeting E-cadherin were purchased from Open Biosystems/Thermo.
Cell culture and immunofluorescence staining. Prostate cancer cell line LNCaP (from ATCC) was cultured in RPMI medium plus 10% unheated FBS. Prostate cancer cell line C4-2 was purchased from Uroco, Inc and cultured in DMEM plus 10% FBS. The stable C4-2 cell line that expresses PKD1-GFP (C4-2/PKD1) was described before (14) . A C4-2 cell line that stably expresses full-length E-cadherin (C4-2/Ecad) was established by antibiotic selection of transit transfected C4-2 cells with the E-cadherin expression vector. The Colon cancer cell line SW480 (from ATCC) was cultured in L15 medium plus 10% FBS. Bryostatin 1 (from Sigma) was added to culture media to a final concentration of 10 nM. In Fig 2C, general PKC inhibitor GF 109203X (GFI, from Sigma) was added to cell culture 1 hour before adding Bryostatin 1 to a final concentration of 1 M. For immunofluorescence imaging, cells cultured on glass discs were fixed in 5% Formalin in PBS for 10 minutes at room temperature.
After washing, primary antibody was diluted in PBS solution with 0.3% Triton X-100 and 10 mg/ml BSA and incubated with fixed cells from 1 hour to overnight following by incubation with secondary antibody conjugated with appropriate dyes (all from Jackson ImmunoResearch). Images were taken by an Olympus IX-51 microscope equipped with SPOT software. Transient transfection was performed with Lipofectamine 2000 (Invitrogen).
Electrophoresis and Western blotting. Cultured cells were lysed in RIPA buffer (20) containing protease and phosphatase inhibitor cocktails (Sigma Chemicals) and centrifuged to removed insoluble debris. The protein samples were separated on 10% SDS-PAGE and transferred to PVDF membranes using a semi-dry transfer devise (Thermo Scientific) at constant current model (0.2 A). The membrane was then incubated with TBST (50 mM Tris-HCl, pH7.4, 100 mM NaCl and 0.2% Tween-20) plus 3% nonfat dry milk to block non-specific binding for 1 hour at room temperature.
Incubation with primary antibodies was performed at 4 C for overnight. An E-cadherin antibody recognizes the intracellular domain (clone C36) was purchased from BD Transduction Laboratories and an antibody that recognizes the extracellular domain was from Santa Cruz Biotechnology. PKD1 and phosphorylated serine-916 (pS916) PKD1 antibodies were purchased from Epitomics. -catenin, -actin and GFP antibodies were purchased from Santa Cruz. The development and characterization of -catenin phosphorylated Threonine-120 antibody was previously described (21) . A phospho-(Ser/Thr) PKD1 substrate antibody which preferably detects LXR(Q/K/E/M)(M/L/K/E/Q/A)S*XXXX ((22)) was purchased from Cell Signaling. The densitometric quantification of immunoblotting was carried out with Image J software.
RESULTS
E-cadherin physically interacts with PKD1
and knockdown E-cadherin decreases PKD1 activity.
PKD1 was previously reported to co-localize with E-cadherin (14) . Since PKD1 was also reported to bind directly to -catenin which is known in a protein complex with Ecadherin (23), it is uncertain if PKD1 association with E-cadherin is through a direct or indirect binding. To explore direct interaction, we tested on yeast 2-hybrid assay using individual PKD1 domains, C1a, C1b, PH and catalytic domain for direct interaction with E-cadherin intracellular domain. As seen in Fig. 1A , the C1b and catalytic domain of PKD1 can directly bind to E-cadherin intracellular domain. The C1b domain of PKD1 is required for binding to DAG and plasma membrane attachment during activation (7, 24) . PKD1 and E-cadherin can be co-immunoprecipitated reciprocally from C4-2/PKD1 cell lysate (Fig 1B) , suggesting that the two proteins are within the same complex in mammalian cells. Since PKD1 is a protein kinase, we also tested in vitro phosphorylation of E-cadherin by PKD1. PKD1 was not able to phosphorylate purified E-cadherin cytoplasm fragment (data not shown). However, we found that expression a shRNA vector that targets E-cadherin in LNCaP, an E-cadherin positive cell line, can reduce PKD1 activation as judged by S916 autophosphorylation (mouse PKD1 animo acid residue, equivalent human PKD1 residue S910) and -catenin T120 transphosphorylation (Fig 1C) . When GFP tagged PKD1 and a shRNA targeting E-cadherin were co-transfected into LNCaP cells, PKD1 predominantly localizes in cytosol of resting cells and knockdown of E-cadherin does not result in noticeably changes on PKD1 localization.
Stimulating agents, such as phorbol esters or Bryostatin 1, a potent PKD1/PKC activator (25) and possible anticancer drug candidate (26), induce PKD1 translocation to different cellular membranes, particularly plasma membrane in cells with control shRNA. In contrast, more PKD1 retains in cytosol in the absence of E-cadherin (Fig 1D) .
Artificial targeting PKD1 to membrane activates PKD1 in the absence of simulations. To further study how binding to E-cadherin might be required for PKD1 activation in vivo, we tested whether membrane recruitment of PKD1 might play a role in activation by artificially targeting it to the membrane. We made a fusion protein construct consisting of the first N-terminal 20 amino acid residues of neuromodulin and full-length PKD1 (mem-PKD1, Fig 2A) . This neuromodulin fragment contains a palmitoylation signal that targets fusion proteins to membranes (27) . When transfected into SW480 cell line, majority of this fusion protein localizes to plasma membrane and small fraction of the protein attaches to organelle membranes (Fig 2E) , while wild type PKD1 localizes in cytoplasm (Fig 2D) . Immunoblotting for pS916 shows that the mem-PKD1 is activated in the absence of stimulation. In contrast, the endogenous PKD1 remains inactive (lane 5, Fig. 2B ) until Bryostatin was added (lane 6). Both C1a and C1b domains of PKD1 can bind to DAG, however, C1b domain is responsible for the majority of DAG binding (15) . Mutation of mouse PKD1 proline-287 residue (equivalent human PKD1 residue P281), a critical DAG binding site within C1b domain abolishes DAG/phorbol ester binding, decreases PKD translocation from cytosol to plasma membrane and prevents PKD activation (9, 15, 28) .
Indeed, the P281G mutant is not able to be activated by Bryostatin as indicated by phosphorylation status of S916 (Lane 4, Fig 2B) . DAG has three functions in activating PKD1: (1) promoting PKD1 membrane translocation; (2) anchoring PKD1 on membrane via hydrophobic tails of DAG; and (3) activating PKCs as upstream kinase activator.
To distinguish the three functions of DAG, we examine the activation of mem-PKD1 with P281G mutation (P281G/mem-PKD1). Like mem-PKD1, the P281G/mem-PKD1, but not the endogenous PKD1, becomes activated without stimulation (lane 7), suggesting targeting wild type or P281G mutant PKD1 to membrane mimics the DAG-induced membrane translocation, activating response normally induced by DAG.
Previous studies suggest that PKCs are the upstream kinases to activate PKD1 in canonical pathway [see review in Ref (7)]. Since the mem-PKD1 can be autophosphorylated in resting cells without upstream active PKCs, we wonder if the activation of mem-PKD1 in resting cells is a PKC-independent event. Indeed, incubation with PKC inhibitor GFI prevents activation of endogenous PKD1 (lane 6, Fig 2C) , but does not block activation of the mem-PKD1 in the absence or presence of Bryostatin 1 (Lanes 5 and 6, Fig 2C) , suggesting that the autoactivation of mem-PKD1 is PKC-independent. Although the exact upstream kinase(s) is elusive, it is certain that targeting PKD1 to plasma membrane brings PKD1 close to the un-identified activator(s).
E-cadherin binding alters PKD1 subcellular localization. When transfected into SW480 which is E-cadherin negative, the wild type GFP-PKD is localized in cytoplasm (Fig 3B) . Co-transfected with full-length E-cadherin, the two proteins are co-localized on cytoplasm and membrane (Fig 3C) , suggesting that the two proteins form a complex in vivo and expression of E-cadherin can affect PKD1 subcellular localization. To further examine how PKD1 subcellular localization is affected by E-cadherin, we tested two additional Ecadherin constructs.
The E-cadherin cytoplasm soluble fragment CTF2 (Fig 3A) is a proteolytic cleavage product that naturally occurs during oncogenesis and apoptosis (29). Overexpression of CTF2 results in colocalization of PKD1 and CTF2 in cytoplasm and nucleus (compare Fig 3B and 3D) . The IL2R-EcadC (Fig 3A) is a chimera that fuses the extracellular and transmembrane domains of the interleukin-2 receptor  subunit to the cytoplasm domain of E-cadherin (18). Coexpression of the IL2R-EcadC and PKD1 induces co-localization of the two proteins (Fig 3E) . We also made a construct that expresses nuclear localized PKD1 by inserting SV40 nuclear localization signal (NLS) into the N-terminus of PKD1 (Fig 2A) . This NLS-PKD1 localizes in nuclei in resting cells ( Fig  3E) . When co-expressed with E-cadherin CTF2 or IL2R-EcadC, the NLS-PKD1 is partially co-localized with the E-cadherin variants in cytoplasm or paranuclear 6 membranes (compare Fig 3E with 3F and 3G) . Taking together, these data strongly suggest that E-cadherin binds to PKD1 and alters PKD1 subcellular localization.
The subcellular localization of activated PKD1 will restrict its biological functions by availability of substrates. We examined PKD1 localization in response to Bryostatin 1 stimulation in the presence or absence of Ecadherin. First, no matter where the initial locations of PKD1 in resting cells, PKD1 become relocated upon stimulation. Figures  2D, 2E and 3E represent PKD1 relocation from cytoplasm, plasma membrane and nuclear, respectively. Second, in the presence of E-cadherin or its variants CTF2 or IL2R-EcadC, activated PKD1 relocation always associates with E-cadherin or its variants (Fig  3) . The wild type PKD1 co-localizes with full-length E-cadherin, CTF2 and IL2R-EcadC at resting and stimulated cells (Fig 3C-3E) . The prominent example is NLS-PKD1, which is partially associated with CTF2 and IL2R-EcadC in resting cells, but it becomes overwhelmingly co-localized with the two Ecadherin variants after stimulation (Fig 3F and  3G) . Although the biological significance of this finding is unknown, it is possible that DAG-induced PKD1 activation would cause PKD1 association with can-related CTF2 fragment and alters PKD1 substrate accessibility.
E-cadherin binding changes the kinetics of PKD1 activation and substrate phosphorylation profiles. We examined the time course of PKD1 activation in C4-2/GFP and C4-2/E-cad cells by immunoblotting pS916. When treated by Bryostatin 1 in C4-2 and C4-2/E-cad cells, the activation course of PKD1 shows dramatically different in the presence and absence of E-cadherin. PKD1 in the control C4-2/GFP cells was slowly activated and it took 2 hours to reach maximum activation (lanes 1-10, Fig 4A) . In contrast, PKD1 in the C4-2/E-cad cells responded quickly and reached peak activation in about 5-10 minutes (lanes 11-20, Fig 4A) . Like PKC isoforms, prolonged stimulation (> 4 hours) results in PKD1 protein degradation (31) . These data suggest that PKD1, in the absence of E-cadherin, has a slow response to stimulation and maintains maximum activation for a short time period. In contrast, E-cadherin binding confers PKD1 a rapid activation and sustainable maximal activity (Fig 4B) .
Next, we ask if the binding of active PKD1 to E-cadherin on plasma membrane will change its substrate phosphorylation profile due to subcellular compartmentation. The antibody pMOTIF recognizes preferred PKD1 phosphorylation motif LxRxxpS/T (where p represents phosphorylated residues) (22). The time courses for PKD1 substrate phosphorylation of C4-2/GFP and C4-2/E-cad cells recognized by pMOTIF antibody are quite different (Fig 4C) . First, the high molecular weight substrates (100-200 kDa) in C4-2/GFP cells have no phosphorylation at resting and become gradually phosphorylated over time to reach peak phosphorylation in about1-2 hours.
The phosphorylation is diminished after 2 hours. Meanwhile, the same protein bands in C4-2/E-cad cells show basal phosphorylation at resting, and maximal phosphorylation can last for at least 4 hours. The difference in kinetics can also be seen at a protein band around 35 kDa (arrowhead in Fig  4C) . The protein is maximally phosphorylated between 30 minutes to 4 hours and is one of the major bands in the C4-2/GFP cells, but it is only weakly phosphorylated in C4-2/E-cad cells. Second, the PKD1 phosphorylates unique substrates in C4-2/GFP cells but not in C4-2/E-cad cells (indicated by * in Fig 4C) . Finally, two bands show strong phosphorylation in resting C4-2/E-cad cells (arrows in Fig 4C) . Activation of PKD1 inhibits the phosphorylation of the two bands as short as 5 minutes. Although the exact mechanism is unknown, one explanation is that the PKD1 basal activity is responsible for phosphorylation in the resting cell, the translocation of PKD1 upon stimulation disassociates PKD1 from its substrates and therefore restricts substrate availability.
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We also tracked PKD1 activation and subcellular localization in a time curse in C4-2 and C4-2/PKD1 cells. Staining for total PKD1 in E-cadherin negative C4-2 cells shows that PKD1 is predominantly in cytoplasm in resting cells. The distribution of PKD1 does not change much until stimulation lasts over 1 hour and PKD1 accumulates around paranuclear and a small portion attaches to plasma membrane (white arrow in Fig 5A) . The active PKD1 (stained for pS916) is not found in resting C4-2 cells, but it becomes detectable 5 minutes after stimulation and it gradually accumulates on plasma membrane and presumably in trans Golgi Network (30) over the time curse (Fig 5A) . In general, the staining patterns of total PKD1 and active PKD1 are partially overlapped but remain different, suggesting not all PKD1 molecules in C4-2 cells are phosphorylated at S916. The C4-2/PKD1 cells stably express wild type PKD1 and induces high level expression of Ecadherin [ref (16) and Fig 5B] . The total PKD1 protein in resting C4-2/PKD1 cells distributes in both cytoplasm and plasma membrane where it co-localizes with Ecadherin (white arrows in Fig 5B) . With longer stimulation, more PKD1 moves to plasma membrane. For unknown reasons, the active PKD1 is ready to detect in resting C4-2/PKD1 cells (Fig 5B) . The active PKD1 accumulates to plasma and organelle membrane over the time. It is obvious that the staining pattern of active PKD1, in the presence of E-cadherin, is more similar to that of the total PKD1, suggesting there are more S916 phosphorylated PKD1 molecules in C4-2/PKD1 cells than those in C4-2 cells.
DISCUSSION
The E-cadherin/-catenin complex is a pivotal epithelial adhesion molecule and regulatory mechanism of Wnt signaling. PKD1 has been reported to associate with E-cadherin (14) and -catenin (23) . In this report, we evaluate the impact of E-cadherin on PKD1 activation. Having shown that the membrane anchored PKD1 can be phosphorylated without stimulation (Fig 1B) , we hypothesize that the membrane-anchored PKD1 versus cytosolic PKD1 have different sequential events during activation upon DAG stimulation. The current PKD1 activation model suggests that DAG plays three roles in PKD1 activation: (1) binding to C1 domain of PKD1 and promotes its membrane translocation; (2) anchoring PKD1 on plasma membrane through DAG hydrophobic tails; (3) activating PKCs as upstream kinases to trans-phosphorylate PKD1. In the case of membrane anchored PKD1, it seems that the activation is independent of DAG and PKCs. This kind of signal cascade has many similar examples in literature. Yeast pheromone response pathway, for example, involves the activation of MAP kinase cascade through G complex and scaffold protein Ste5. Pheromone exposure promotes membrane translocation of Ste5, along with associated inactive MAP kinases, and binds to membrane Gand thus the MAP kinases get accessed to proximate upstream kinase Ste20. Membrane recruitment of Ste5 by G complex can be bypassed with artificial targeting Ste5 to the plasma membrane in the absence of pheromone (32) .
In this report, we present evidence that Ecadherin is required for PKD1 optimal membrane attachment and activation. We emphasize the role of E-cadherin in regulation of PKD1 activity and localization. Our major findings are: (1) PKD1 has distinct kinetics of activation in the presence or absence of Ecadherin (Fig 4A and 4B ). In the presence of E-cadherin, PKD1 activation is rapid and sustained. In contrast, it takes much longer time (2 hours) for PKD1 to reach maximal activity in response to the same stimulation in the absence of E-cadherin. This difference in kinetics may physiologically cause significant difference for PKD1 in response to short life signals in a cell; and (2) E-cadherin affects PKD1 subcellular localization (Fig 3B and  3C) . Since PKD1 is a potential inhibitor for epithelial to mesenchymal transition (16, 33) , the disruption of PKD1 subcellular localization by loss of E-cadherin may contribute to metastasis. In addition, our data shows that the soluble E-cadherin cytoplasm fragment CTF2 can also bind to and alter PKD1 subcellular localization (Fig 3D) .
Although the biological significance of this alteration is still to be evaluated, it is tempting to assume that PKD1 may play different functions in the presence of E-cadherin CTF2 during tumorigenesis; and (3) the PKD1 substrate phosphorylation shows dramatically distinct patterns with or without E-cadherin (Fig 4C) , suggesting that PKD1 may phosphorylate different substrates and regulate different signal pathways and biological events in context of E-cadherin.
In non-epithelial cells, PKD1 may partner with other proteins to achieve optimal activation. One example is B cell antigen receptor (BCR) engagement, which leads to activates both PKD1 and Bruton's tyrosine kinase (Btk) (34) . It has been reported that PKD1 physically associates with Btk (35) and Btk-deficiency diminishes PKD1 activation (34), suggesting Btk is required for PKD1 activation. However, Haxhinasto and Bishop found that a naturally occurred dominant negative form of Btk (xid, which contains point mutant R28C) does not abrogate PKD1 activation in B cells (36) and the authors proposed that the role of Btk is not to directly activate PKD1, but rather to cooperate with PKD1-mediated signals as an adaptor protein (36) . The PKD1 protein contains multiple regulatory domains which can recruit interacting proteins. For example, the C-termini of PKD1 and PKD2 have a PDZ-binding motif and both isoforms can bind to membrane localized PDZ domaincontaining protein NHERF-1 (37). Importantly, agonist-evoked activation of PKD in the presence of the NHERF-1 scaffold is rapid and sustained compared with cytosolic PKD (37) . In HEK293 cells, the C1b domain of PKD1 directly binds to G-protein Galphaq subunit, and the binding contributes to longlasting activation of PKD1 on plasma membrane (38) . Therefore, our results provide an alternative explanation for the diverse functions of PKD1, i.e. protein-protein interactions are a mechanism for PKD1 regulation, poising PKD1 near upstream kinases and lipid regulators and near specific substrates.
Taken together, our data suggest that Ecadherin provides PKD1 a membrane anchorage and facilitates PKD1 activation in epithelial cells through the interaction of PKD1 with E-cadherin cytoplasm domain. Since PKD1 can suppress the function of transcription factor Snail, a known repressor of E-cadherin expression and up-regulate Ecadherin expression (16), the two proteins form a positive feedback loop that involves transcriptional as well as kinase regulation, favoring maintenance of epithelial cell identity. Loss of E-cadherin expression or cancer-related proteolysis of E-cadherin that generates soluble CTF2 can alter PKD1 localization and function.
Our results demonstrate that spatial and temporal organization of the PKD1 signal transduction is essential in determining the speed and precision by which signaling events occur. Targeting of PKD1 to the membrane activates PKD1 without stimulation.
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